Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bosnia | Brazil | Croatia | India | Ireland | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other
Phase 2: Amyotrophic Lateral Sclerosis|Alzheimer Disease|Peripheral Nervous System Diseases|Hereditary Sensory and Autonomic Neuropathies
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400089707 | N/A |
Not yet recruiting |
Kidney Diseases |
2026-01-01 |
|
| SENSE | P2 |
Recruiting |
Hereditary Sensory and Autonomic Neuropathies |
2025-08-01 |
|
| 2022-000241-32 | P3 |
Active, not recruiting |
Other |
2025-06-30 |
|
| FATHIS+ | N/A |
Recruiting |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Obesity, Abdominal |
2025-05-01 |